These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11389071)

  • 1. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
    Feldkamp MM; Lau N; Roncari L; Guha A
    Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
    Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
    Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
    J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
    Peters DG; Hoover RR; Gerlach MJ; Koh EY; Zhang H; Choe K; Kirschmeier P; Bishop WR; Daley GQ
    Blood; 2001 Mar; 97(5):1404-12. PubMed ID: 11222387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
    Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P
    J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
    Smalley KS; Eisen TG
    Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferation of human malignant astrocytomas is dependent on Ras activation.
    Guha A; Feldkamp MM; Lau N; Boss G; Pawson A
    Oncogene; 1997 Dec; 15(23):2755-65. PubMed ID: 9419966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336.
    Glass TL; Liu TJ; Yung WK
    Neuro Oncol; 2000 Jul; 2(3):151-8. PubMed ID: 11302335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
    Ashar HR; James L; Gray K; Carr D; McGuirk M; Maxwell E; Black S; Armstrong L; Doll RJ; Taveras AG; Bishop WR; Kirschmeier P
    Exp Cell Res; 2001 Jan; 262(1):17-27. PubMed ID: 11120601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
    Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the farnesyltransferase inhibitor B1620.
    Kurimoto M; Hirashima Y; Hamada H; Kamiyama H; Nagai S; Hayashi N; Endo S
    J Neurooncol; 2003 Jan; 61(2):103-12. PubMed ID: 12622448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
    Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
    Nielsen LL; Shi B; Hajian G; Yaremko B; Lipari P; Ferrari E; Gurnani M; Malkowski M; Chen J; Bishop WR; Liu M
    Cancer Res; 1999 Dec; 59(23):5896-901. PubMed ID: 10606231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Farnesyl transferase inhibitors: one target may be found in another].
    Mazières J; Pradines A; Favre G
    Med Sci (Paris); 2003 Feb; 19(2):211-6. PubMed ID: 12836615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyl transferase inhibitors in the treatment of breast cancer.
    Kelland LR
    Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.